HIV-1 mediated immune pathogenesis: Spotlight on the role of viral protein R (VPR)

Current HIV Research

Volumn 7, Issue 2, 2009, Pages 169-177

  Majumder, Biswanath ^a   Venkatachari, Narasimhan J ^a   Srinivasan, Alagarsamy ^b,c   Ayyavoo, Velpandi ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NanoBio Diagnostics   (United States)

Author keywords

Dendritic cells; HIV 1 Vpr; Immune function; Immunopathogenesis; NK cells; T cells

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ALPHA INTERFERON; ATR PROTEIN; HLA B7 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; NEF PROTEIN; PROTEIN TYROSINE PHOSPHATASE; TRANSACTIVATOR PROTEIN; VIRUS DNA; VPR PROTEIN; VIRULENCE FACTOR; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL NUCLEUS MEMBRANE; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA STRAND BREAKAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PATHOGENICITY; PHYSIOLOGY;

HIV-1; HUMANS; IMMUNE TOLERANCE; VIRULENCE FACTORS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 64749100822     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209787581445     Document Type: Review

References (106)

1. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. Viral immune evasion: a masterpiece of evolution. Immunogenetics 2002; 54: 527-42.
2. Finlay BB, McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 2006; 124: 767-82.
3. Johnson WE, Desrosiers RC. Viral persistance: HIV's strategies of immune system evasion. Annu Rev Med 2002; 53: 499-518.
4. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol 2000; 18: 861-926.
5. Mahalingam S, Meanger J, Foster PS, Lidbury BA. The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses. J Leukoc Biol 2002; 72: 429-39.
6. Malim MH, Emerman M. HIV-1 accessory proteins - ensuring viral survival in a hostile environment. Cell Host Microbe 2008; 3: 388-98.
7. Levy JA. HIV pathogenesis: knowledge gained after two decades of research. Adv Dent Res 2006; 19: 10-6.
8. Cohen EA, Dehni G, Sodroski JG, Haseltine WA. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 1990; 64: 3097-9.
9. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995; 206: 935-44.
10. Freed EO, Englund G, Martin MA. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol 1995; 69: 3949-54.
11. Subbramanian RA, Kessous-Elbaz A, Lodge R, et al. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med 1998; 187: 1103-11.
12. Eckstein DA, Sherman MP, Penn ML, et al. HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med 2001; 194: 1407-19.
13. Campbell BJ, Hirsch VM. Vpr of simian immunodeficiency virus of African green monkeys is required for replication in macaque macrophages and lymphocytes. J Virol 1997; 71: 5593-602.
14. Lang SM, Weeger M, Stahl-Hennig C, et al. Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol 1993; 67: 902-12.
15. Gibbs JS, Lackner AA, Lang SM, et al. Progression to AIDS in the absence of a gene for vpr or vpx. J Virol 1995; 69: 2378-83.
16. Goh WC, Rogel ME, Kinsey CM, et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 1998; 4: 65-71.
17. Hirsch VM, Sharkey ME, Brown CR, et al. Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med 1998; 4: 1401-8.
18. Wang B, Ge YC, Palasanthiran P, et al. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology 1996; 223: 224-32.
19. Yedavalli VR, Ahmad N. Low conservation of functional domains of HIV type 1 vif and vpr genes in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retroviruses 2001; 17: 911-23.
20. Yedavalli VR, Chappey C, Ahmad N. Maintenance of an intact human immunodeficiency virus type 1 vpr gene following mother-to-infant transmission. J Virol 1998; 72: 6937-43.
21. Michael NL, Chang G, d'Arcy LA, et al. Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol 1995; 69: 4228-36.
22. Saksena NK, Wang B, Ge YC, Xiang SH, Dwyer DE, Cunningham AL. Coinfection and genetic recombination between HIV-1 strains: possible biological implications in Australia and South East Asia. Ann Acad Med Singapore 1997; 26: 121-7.
23. Suzuki Y, Misawa N, Sato C, et al. Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells. Virus Genes 2003; 27: 177-88.
24. Jacquot G, Le Rouzic E, David A, et al. Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology 2007; 4: 84.
25. Iordanskiy S, Zhao Y, DiMarzio P, Agostini I, Dubrovsky L, Bukrinsky M. Heat-shock protein 70 exerts opposing effects on Vpr-dependent and Vpr-independent HIV-1 replication in macrophages. Blood 2004; 104: 1867-72.
26. Vodicka MA, Koepp DM, Silver PA, Emerman M. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998; 12: 175-85.
27. de Noronha CM, Sherman MP, Lin HW, et al. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 2001; 294: 1105-8.
28. Segura-Totten M, Wilson KL. Virology. HIV - breaking the rules for nuclear entry. Science 2001; 294: 1016-7.
29. Popov S, Rexach M, Zybarth G, et al. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. Embo J 1998; 17: 909-17.
30. Heinzinger NK, Bukinsky MI, Haggerty SA, et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91: 7311-5.
31. Wiegers K, Schwarck D, Reimer R, Bohn W. Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology 2008; 375: 73-84.
32. Wiegers K, Schwarck D, Reimer R, Bohn W. Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology 2008; 375: 73-84.
33. Vanitharani R, Mahalingam S, Rafaeli Y, et al. HIV-1 Vpr transactivates LTR-directed expression through sequences present within - 278 to -176 and increases virus replication in vitro. Virology 2001; 289: 334-42.
34. Poon B, Chang MA, Chen IS. Vpr is required for efficient Nef expression from unintegrated human immunodeficiency virus type 1 DNA. J Virol 2007; 81: 10515-23.
35. Ayyavoo V, Mahalingam S, Rafaeli Y, et al. HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. J Leukoc Biol 1997; 62: 93-9.
36. Ayyavoo V, Rafaeli Y, Nagashunmugam T, et al. HIV-1 viral protein R (Vpr) as a regulator of the target cell. Psychoneuroendocrinology 1997; 22: S41-9.
37. Ayyavoo V, Mahboubi A, Mahalingam S, et al. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med 1997; 3: 1117-23.
38. Muthumani K, Bagarazzi M, Conway D, et al. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J Med Primatol 2002; 31: 179-85.
39. Ayyavoo V, Muthumani K, Kudchodkar S, et al. HIV-1 viral protein R compromises cellular immune function in vivo. Int Immunol 2002; 14: 13-22.
40. Muthumani K, Hwang DS, Choo AY, et al. HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 2005; 17: 103-16.
41. Majumder B, Janket ML, Schafer EA, et al. Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape. J Virol 2005; 79: 7990-8003.
42. Teeuwsen VJ, Siebelink KH, de Wolf F, Goudsmit J, UytdeHaag FG, Osterhaus AD. Impairment of in vitro immune responses occurs within 3 months after HIV-1 seroconversion. AIDS 1990; 4: 77-81.
43. Conti L, Matarrese P, Varano B, et al. Dual role of the HIV-1 vpr protein in the modulation of the apoptotic response of T cells. J Immunol 2000; 165: 3293-300.
44. Zhu Y, Gelbard HA, Roshal M, Pursell S, Jamieson BD, Planelles V. Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. J Virol 2001; 75: 3791-801.
45. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 2002; 169: 6361-8.
46. McAllister JJ, Phillips D, Millhouse S, et al. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell typespecific gene regulation and viral replication. Virology 2000; 274: 262-77.
47. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 1995; 270: 25564-9.
48. Venkatachari NJ, Majumder B, Ayyavoo V. Human immunodeficiency virus (HIV) type 1 Vpr induces differential regulation of T cell costimulatory molecules: direct effect of Vpr on T cell activation and immune function. Virology 2007; 358: 347-56.
49. Majumder B, Venkatachari NJ, Schafer EA, Janket ML, Ayyavoo V. Dendritic cells infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha. J Virol 2007; 81: 7388-99.
50. Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci USA 2004; 101: 7669-74.
51. Ma X, Montaner LJ. Proinflammatory response and IL-12 expression in HIV-1 infection. J Leukoc Biol 2000; 68: 383-90.
52. Smed-Sorensen A, Lore K, Walther-Jallow L, Andersson J, Spetz AL. HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood 2004; 104: 2810-7.
53. Muthumani K, Desai BM, Hwang DS, et al. HIV-1 Vpr and anti-inflammatory activity. DNA Cell Biol 2004; 23: 239-47.
54. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev 1997; 159: 119-35.
55. He L, Terunuma H, Hanabusa H, et al. Interleukin 18 and interleukin 1beta production is decreased in HIV type 1-seropositive hemophiliacs but not in HIV type 1-seropositive nonhemophiliacs. AIDS Res Hum Retroviruses 2000; 16: 345-53.
56. Torre D, Speranza F, Martegani R, et al. Circulating levels of IL-18 in adult and paediatric patients with HIV-1 infection. Aids 2000; 14: 2211-2.
57. Almeida M, Cordero M, Almeida J, Orfao A. Abnormal cytokine production by circulating monocytes and dendritic cells of myeloid origin in ART-treated HIV-1+ patients relates to CD4+ T-cell recovery and HCV co-infection. Curr HIV Res 2007; 5: 325-36.
58. Fantuzzi L, Conti L, Gauzzi MC, et al. Regulation of chemokine/ cytokine network during in vitro differentiation and HIV-1 infection of human monocytes: possible importance in the pathogenesis of AIDS. J Leukoc Biol 2000; 68: 391-9.
59. Biancotto A, Grivel JC, Iglehart SJ, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007; 109: 4272-9.
60. Majumder B, Venkatachari NJ, O'Leary S, Ayyavoo V. Infection with Vpr-positive human immunodeficiency virus type 1 impairs NK cell function indirectly through cytokine dysregulation of infected target cells. J Virol 2008; 82: 7189-200.
61. Liu B, Li Z, Mahesh SP, et al. Glucocorticoid-induced Tumor Necrosis Factor Receptor Negatively Regulates Activation of Human Primary Natural Killer (NK) Cells by Blocking Proliferative Signals and Increasing NK Cell Apoptosis. J Biol Chem 2008; 283: 8202-10.
62. Nakamura T, Suzuki H, Okamoto T, et al. Recombinant Vpr (rVpr) causes augmentation of HIV-1 p24 Ag level in U1 cells through its ability to induce the secretion of TNF. Virus Res 2002; 90: 263-8.
63. Henoch Hong BN, schubert U, Ballmaier M, et al. HIV-1 Vpr Inhibition of Plasmacytoid Dendritic cell derived type I interferon and impairment of pDC-NK cell crosstalk in vitro. 15th Conference on retroviruses and opportunistic infections 2008.
64. Chensue SW. Molecular machinations: chemokine signals in host-pathogen interactions. Clin Microbiol Rev 2001; 14: 821-35, table of contents.
65. Muthumani K, Kudchodkar S, Papasavvas E, Montaner LJ, Weiner DB, Ayyavoo V. HIV-1 Vpr regulates expression of beta chemokines in human primary lymphocytes and macrophages. J Leukoc Biol 2000; 68: 366-72.
66. Andersen JL, Planelles V. The role of Vpr in HIV-1 pathogenesis. Curr HIV Res 2005; 3: 43-51.
67. Gougeon ML. Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol 2003; 3: 392-404.
68. Finkel TH, Tudor-Williams G, Banda NK, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995; 1: 129-34.
69. Rosok BI, Brinchmann JE, Stent G, et al. Correlates of apoptosis of CD4+ and CD8+ T cells in tonsillar tissue in HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14: 1635-43.
70. Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995; 154: 5555-66.
71. Moretti S, Marcellini S, Boschini A, et al. Apoptosis and apoptosis-associated perturbations of peripheral blood lymphocytes during HIV infection: comparison between AIDS patients and asymptomatic long-term non-progressors. Clin Exp Immunol 2000; 122: 364-73.
72. Azad AA. Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells? Biochem Biophys Res Commun 2000; 267: 677-85.
73. Deniaud A, Brenner C, Kroemer G. Mitochondrial membrane permeabilization by HIV-1 Vpr. Mitochondrion 2004; 4: 223-33.
74. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003; 300: 1295-7.
75. Huard S, Elder RT, Liang D, Li G, Zhao RY. HIV-1 Vpr induces cell cycle G2 arrest through Srk1/MK2-mediated phosphorylation of Cdc25. J Virol 2008; 82: 2904-17.
76. Kino T, Gragerov A, Valentin A, et al. Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Virol 2005; 79: 2780-7.
77. Bernardi P, Petronilli V, Di Lisa F, Forte M. A mitochondrial perspective on cell death. Trends Biochem Sci 2001; 26: 112-7.
78. Yedavalli VS, Shih HM, Chiang YP, et al. Human immunodeficiency virus type 1 Vpr interacts with antiapoptotic mitochondrial protein HAX-1. J Virol 2005; 79: 13735-46.
79. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 2003; 278: 25879-86.
80. Lai M, Zimmerman ES, Planelles V, Chen J. Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol 2005; 79: 15443-51.
81. Tachiwana H, Shimura M, Nakai-Murakami C, et al. HIV-1 Vpr induces DNA double-strand breaks. Cancer Res 2006; 66: 627-31.
82. Shimura M, Tanaka Y, Nakamura S, et al. Micronuclei formation and aneuploidy induced by Vpr, an accessory gene of human immunodeficiency virus type 1. Faseb J 1999; 13: 621-37.
83. Gibellini D, Re MC, Ponti C, et al. HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: a potential molecular mechanism to escape TRAIL cytotoxicity. J Cell Physiol 2005; 203: 547-56.
84. Varin A, Decrion AZ, Sabbah E, et al. Synthetic Vpr protein activates activator protein-1, c-Jun N-terminal kinase, and NF-kappaB and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. J Biol Chem 2005; 280: 42557-67.
85. Muthumani K, Choo AY, Zong WX, et al. The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol 2006; 8: 170-9.
86. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 2007; 3: e85.
87. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 2007; 4: 57.
88. Zhao LJ, Jian H, Zhu H. HIV-1 auxiliary regulatory protein Vpr promotes ubiquitination and turnover of Vpr mutants containing the L64P mutation. FEBS Lett 2004; 563: 170-8.
89. Alter G, Teigen N, Davis BT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005; 106: 3366-9.
90. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10: 661-71.
91. Ahmad A, Ahmad R. HIV's evasion of host's NK cell response and novel ways of its countering and boosting anti-HIV immunity. Curr HIV Res 2003; 1: 295-307.
92. Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci USA 2003; 100: 15011-6.
93. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol 2005; 5: 835-43.
94. Collins KL, Baltimore D. HIV's evasion of the cellular immune response. Immunol Rev 1999; 168: 65-74.
95. Zocchi MR, Rubartelli A, Morgavi P, Poggi A. HIV-1 Tat inhibits human natural killer cell function by blocking L-type calcium channels. J Immunol 1998; 161: 2938-43.
96. Poggi A, Carosio R, Spaggiari GM, et al. NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J Immunol 2002; 168: 95-101.
97. Azzoni L, Rutstein RM, Chehimi J, Farabaugh MA, Nowmos A, Montaner LJ. Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children. J Infect Dis 2005; 191: 1451-9.
98. Korber BTM, Brander C, Hayens BF, et al. HIV Molecular Immunology, Los Alamos National Laboratory, Los Alamos, NM. 2007.
99. Brumme ZL, Brumme CJ, Heckerman D, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/ regulatory genes of HIV-1. PLoS Pathog 2007; 3: e94.
100. Novitsky V, Cao H, Rybak N, et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 2002; 76: 10155-68.
101. Yusim K, Kesmir C, Gaschen B, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002; 76: 8757-68.
102. Altfeld M, Addo MM, Eldridge RL, et al. Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol 2001; 167: 2743-52.
103. Altfeld MA, Livingston B, Reshamwala N, et al. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol 2001; 75: 1301-11.
104. Castelli FA, Houitte D, Munier G, et al. Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively. Eur J Immunol 2008; 38: 2821-31.
105. Srinivasan A, Ayyavoo V, Mahalingam S, et al. A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: potential impact on CTL epitopes. Virol J 2008; 5: 99.
106. Rousseau CM, Daniels MG, Carlson JM, et al. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol 2008; 82: 6434-46.